Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CYCLOSET

« Back to Dashboard
Cycloset is a drug marketed by Veroscience and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug.

This drug has one hundred and twenty-five patent family members in twenty-eight countries.

The generic ingredient in CYCLOSET is bromocriptine mesylate. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

Summary for Tradename: CYCLOSET

Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: see list3

Pharmacology for Tradename: CYCLOSET

Ingredient-typeErgolines
Drug ClassErgot Derivative

Clinical Trials for: CYCLOSET

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects
Status: Recruiting Condition: Type 2 Diabetes

Effect of Cycloset on Glycemic Control When Added to GLP-1 Analogue Therapy
Status: Recruiting Condition: Type 2 Diabetes

Bromocriptine and Insulin Sensitivity
Status: Recruiting Condition: Insulin Sensitivity

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes Mellitus

Vaginal Bromocriptine for Treatment of Adenomyosis
Status: Active, not recruiting Condition: Adenomyosis

Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study
Status: Not yet recruiting Condition: PCOS; Insulin Resistance

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
Status: Recruiting Condition: Parkinson's Disease

Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy
Status: Recruiting Condition: Peripartum Cardiomyopathy

Bromocriptine in the Treatment of Peripartum Cardiomyopathy
Status: Not yet recruiting Condition: Peripartum Cardiomyopathy

Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes
Status: Recruiting Condition: Type 1 Diabetes

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 2009RXYes5,716,957<disabled> <disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 2009RXYes8,137,994<disabled> <disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 2009RXYes8,431,155<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CYCLOSET

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 20095,468,755<disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 20095,866,584<disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 20095,679,685<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: CYCLOSET

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,872,133 Method of regulating the immune response<disabled in preview>
5,719,160 Method for modifying and regulating lipid metabolism<disabled in preview>
5,760,047 Method for treatment of obesity using prolactin modulators and diet<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CYCLOSET

Country Document Number Publication Date
Canada2872300Nov 07, 2013
European Patent Office0917874May 26, 1999
European Patent Office2437732Oct 31, 2012
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc